Vogler M, Dürr K, Jovanovic M, Debatin K-M, Fulda S
University Children's Hospital, Ulm, Germany.
Oncogene. 2007 Jan 11;26(2):248-57. doi: 10.1038/sj.onc.1209776. Epub 2006 Jul 10.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer therapy because of its relative tumor selectivity. However, many cancers including pancreatic cancer remain resistant towards TRAIL. To develop TRAIL for cancer therapy of pancreatic carcinoma, it will therefore be pivotal to elucidate the molecular mechanisms of TRAIL resistance. Here, we identify X-linked inhibitor of apoptosis (XIAP) as a regulator of TRAIL sensitivity in pancreatic carcinoma cells. Full activation of effector caspases, loss of mitochondrial membrane potential and cytochrome c release following TRAIL treatment were markedly impaired in pancreatic carcinoma cell lines, which poorly responded to TRAIL (PaTuII, PancTu1, ASPC1, DanG), compared to TRAIL-sensitive Colo357 pancreatic carcinoma cells. Stable downregulation of XIAP by RNA interference significantly reduced survival and enhanced TRAIL-induced apoptosis in pancreatic carcinoma cells. Also, downregulation of XIAP significantly increased CD95-induced cell death. Importantly, knockdown of XIAP strongly inhibited clonogenicity of pancreatic cancer cells treated with TRAIL indicating that XIAP promotes clonogenic survival of pancreatic carcinoma cells. Thus, our findings for the first time indicate that targeting XIAP represents a promising strategy to enhance the antitumor activity of TRAIL in pancreatic cancer, which has important clinical implications.
肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)因其相对的肿瘤选择性而成为癌症治疗的一个有前景的候选药物。然而,包括胰腺癌在内的许多癌症对TRAIL仍具有抗性。为了将TRAIL用于胰腺癌的癌症治疗,因此阐明TRAIL抗性的分子机制将是关键。在这里,我们确定X连锁凋亡抑制蛋白(XIAP)是胰腺癌细胞中TRAIL敏感性的调节因子。与对TRAIL敏感的Colo357胰腺癌细胞相比,TRAIL处理后效应半胱天冬酶的完全激活、线粒体膜电位的丧失和细胞色素c的释放,在对TRAIL反应不佳的胰腺癌细胞系(PaTuII、PancTu1、ASPC1、DanG)中明显受损。通过RNA干扰稳定下调XIAP可显著降低胰腺癌细胞的存活率并增强TRAIL诱导的凋亡。此外,XIAP的下调显著增加了CD95诱导的细胞死亡。重要的是,XIAP的敲低强烈抑制了用TRAIL处理的胰腺癌细胞的克隆形成能力,表明XIAP促进胰腺癌细胞的克隆存活。因此,我们的研究结果首次表明,靶向XIAP是增强TRAIL在胰腺癌中抗肿瘤活性的一种有前景的策略,这具有重要的临床意义。